Human Metabolome Technologies Inc. (HMT) President and CEO Ryuji Kanno announced today that the joint patent application for Phosphoethanolamine as a biomarker of MDD was granted in the EU. This was conducted in collaboration with Noriyuki Kawamura, Director of the Medical Corporation Association Gyo-ki kai Kawamura General Clinic (Minato-ku, Tokyo), and has officially been accepted and granted in the European market. This is in addition to the registration of the patents in Japan, USA, and China. The corresponding patent identification numbers are 5372213 in Japan), US8951739 in the USA and ZL201080046087.6 in China). The EU patent grant will not have any impact on
business performance